Sutezolid
Partners: Bill & Melinda Gates Medical Research Institute, The Aurum Institute, AIDS Clinical Trial Group (ACTG), Otsuka Pharmaceutical
Background:
Research:
Sutezolid is in the same class of drugs as linezolid (oxazolidinones). Tests conducted over the past decade have indicated that sutezolid may have an improved therapeutic potential when compared to linezolid, which is currently recommended by the World Health Organization as a treatment option for drug-resistant forms of TB.
Sutezolid is currently being studied in three programs:
- PAN-HM, in collaboration with The Aurum Institute
- PAN-TB, in collaboration with Gates MRI, Janssen, and Otsuka
- RAD-TB, in collaboration with ACTG
TB Alliance is committed to making sutezolid data and drug material available to the research community. For more information, please visit:
- Single Ascending-Dose Study To Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid in Healthy Adult Subjects | Antimicrob Agents Chemother
- Contribution of the Nitroimidazoles PA-824 and TBA-354 to the Activity of Novel Regimens in Murine Models of Tuberculosis | Antimicrob Agents Chemother
- Sterilizing Activities of Novel Combinations Lacking First- and Second-Line Drugs in a Murine Model of Tuberculosis | Antimicrob Agents Chemother
- Global tuberculosis drug development pipeline: the need and the reality | Lancet